The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis

Pirfenidone is a recently approved antifibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF). Because tuberculosis (TB) is characterized by granulomatous inflammation in conjunction with parenchymal destruction and replacement fibrosis, we sought to determine whether the addition of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCI Insight
Autors principals: Ahidjo, Bintou A., Maiga, Mariama C., Ihms, Elizabeth A., Maiga, Mamoudou, Ordonez, Alvaro A., Cheung, Laurene S., Beck, Sarah, Andrade, Bruno B., Jain, Sanjay, Bishai, William R.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033951/
https://ncbi.nlm.nih.gov/pubmed/27699232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.86017
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars